Congia S, Tronci S, Ledda M, Porcella A, Coppola G
Cattedra di Patologia Speciale Neurologica della Università di Cagliari.
Ital J Neurol Sci. 1991 Apr;12(2):193-8. doi: 10.1007/BF02337033.
30 subjects--23 with amyotrophic lateral sclerosis (ALS), 4 with Charcot-Marie Tooth atrophy, 2 with progressive spinal muscle atrophy and 1 with radiation myelopathy--were given chronic low-dose TRH therapy. The effects of treatment were assessed on the scale of Norris et al. (1974). The outcome of the study, in agreement with some and at variance with other studies, was that TRH induced a statistically significant neurological improvement in 17 of the 23 ALS patients but little or none in the other ALS patients and in patients with other neurological diseases.
30名受试者——23例肌萎缩侧索硬化症（ALS）患者、4例夏科-马里-图斯萎缩症患者、2例进行性脊髓性肌萎缩症患者和1例放射性脊髓病患者——接受了慢性低剂量促甲状腺激素释放激素（TRH）治疗。根据诺里斯等人（1974年）的量表评估治疗效果。该研究结果与一些研究一致，但与其他研究不同，即TRH使23例ALS患者中的17例在神经学方面有统计学意义的改善，而在其他ALS患者以及患有其他神经疾病的患者中几乎没有或没有改善。
